198 related articles for article (PubMed ID: 11510030)
1. Gemcitabine/carboplatin in advanced urothelial cancer.
Carles J; Nogué M
Semin Oncol; 2001 Jun; 28(3 Suppl 10):19-24. PubMed ID: 11510030
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium.
Xu N; Zhang XC; Xiong JP; Fang WJ; Yu LF; Qian J; Zhang L
BMC Cancer; 2007 Jun; 7():98. PubMed ID: 17559681
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A;
Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574
[TBL] [Abstract][Full Text] [Related]
4. Current and future perspectives in advanced bladder cancer: is there a new standard?
von der Maase H
Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Albanell J; Tabernero JM; Cortés-Funes H; Baselga J
Eur J Cancer; 2000 Jul; 36 Suppl 2():17-25. PubMed ID: 10908844
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine Plus Cisplatin Split
Izumi K; Iwamoto H; Yaegashi H; Shigehara K; Nohara T; Kadono Y; Mizokami A
In Vivo; 2019; 33(1):167-172. PubMed ID: 30587618
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Hainsworth JD; Meluch AA; Litchy S; Schnell FM; Bearden JD; Yost K; Greco FA
Cancer; 2005 Jun; 103(11):2298-303. PubMed ID: 15856431
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
Dogliotti L; Cartenì G; Siena S; Bertetto O; Martoni A; Bono A; Amadori D; Onat H; Marini L
Eur Urol; 2007 Jul; 52(1):134-41. PubMed ID: 17207911
[TBL] [Abstract][Full Text] [Related]
9. [Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
Helke C; May M; Hoschke B
Aktuelle Urol; 2006 Sep; 37(5):363-8. PubMed ID: 17004181
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
Hoshi S; Ohyama C; Ono K; Takeda A; Yamashita S; Yamato T; Itoh A; Satoh M; Saito S; Okada Y; Sohma F; Arai Y
Int J Clin Oncol; 2004 Apr; 9(2):125-9. PubMed ID: 15108045
[TBL] [Abstract][Full Text] [Related]
11. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).
De Santis M; Wiechno PJ; Bellmunt J; Lucas C; Su WC; Albiges L; Lin CC; Senkus-Konefka E; Flechon A; Mourey L; Necchi A; Loidl WC; Retz MM; Vaissière N; Culine S
Ann Oncol; 2016 Mar; 27(3):449-54. PubMed ID: 26673352
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function.
Carles J; Nogué M; Domènech M; Pérez C; Saigí E; Villadiego K; Guasch I; Ibeas R
Oncology; 2000 Jun; 59(1):24-7. PubMed ID: 10895062
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Halim A; Abotouk N
Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond.
Cheng T
Curr Opin Support Palliat Care; 2008 Sep; 2(3):153-60. PubMed ID: 18685414
[TBL] [Abstract][Full Text] [Related]
15. Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract.
Park JH; Lee SW; Kim HS; Kang SG; Ko YH; Kim ST; Kang SH; Park YJ; Choi IK; Oh SC; Sung DJ; Seo JH; Cheon J; Kim YH; Kim JS; Park KH
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1033-9. PubMed ID: 23370665
[TBL] [Abstract][Full Text] [Related]
16. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Oing C; Rink M; Oechsle K; Seidel C; von Amsberg G; Bokemeyer C
J Urol; 2016 Feb; 195(2):254-63. PubMed ID: 26410730
[TBL] [Abstract][Full Text] [Related]
17. Our experience with 23 consecutive patients on gemcitabine/carboplatin chemotherapy for treatment of metastasized transitional cell carcinoma of the urothelium.
Hoschke B; May M; Seehafer M; Helke C
Int J Urol; 2004 Jul; 11(7):461-6. PubMed ID: 15242353
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.
Smith DC; Mackler NJ; Dunn RL; Hussain M; Wood D; Lee CT; Sanda M; Vaishampayan U; Petrylak DP; Quinn DI; Beekman K; Montie JE
J Urol; 2008 Dec; 180(6):2384-8; discussion 2388. PubMed ID: 18930256
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.
Bellmunt J; Albiol S; de Olano AR; Pujadas J; Maroto P;
Ann Oncol; 2006 May; 17 Suppl 5():v113-7. PubMed ID: 16807437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
